Patent · US Active

Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof

US7910097B2 · kind B2 · utility

4Cited by

5References

13Claims

0Family size

Assignee

FARON PHARMACEUTICALS OY · FI

Inventors

Sirpa Jalkanen · Kaarina, FI
Heikki Irjala · Turku, FI
Marko Salmi · Turku, FI

Key dates

Filing date	Mar 5, 2008
Grant date	Mar 22, 2011
Priority date	—
Expiry date	May 20, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.